AMGN compared with LCTX: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

LCTXLineage Cell Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

LCTXLineage Cell Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

Q3 FY25±3.7%▲+7.81%×2.11

LCTX1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−2.65%—

= impliedAMGN realized, solidLCTX realized, hatchedOne scale, both sides: full bar = 9%× = |realized| ÷ impliedSource: market data

AMGNAmgen Inc

464.40▼−0.35%

Mkt cap$251.9BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

LCTXLineage Cell Therapeutics, Inc.

1.00▼−0.09%

Regular sessionSep 2 '83

Mkt cap$252.9MRevenue$1MQ2 FY26Revenue$15MFY25

Compare

Regular sessionSep 2 '83

AMGNAmgen Inc

LCTXLineage Cell Therapeutics, Inc.

464.40▼−0.35%

Price

1.00▼−0.09%

$251.9B

Mkt cap

$252.9M

Q2 FY26$10.1B

Revenue

$1MQ2 FY26

FY25$36.8B

Revenue

$15MFY25

AMGN464.40▼−0.35%vsLCTX1.00▼−0.09%Regular sessionSep 2 '83